Corona vaccine partial success in India, given to 1600 patients

(PTI) New Delhi, Ta. Monday, August 3, 2020

The vaccine, developed by Oxford University of Corona in India, has received approval for the second and third phases of the trial. The first phase of the trial has already taken place.

The second and third phases of the vaccine, developed by Oxford University in Britain, were approved today by The Drug Controller General of India. The vaccine is now being tested on about 1600 patients in 17 different parts of the country. Any vaccine is prepared only after various tests.

The Oxford vaccine is also being tested in Britain. Testing has been approved in India, Brazil and South Africa after initial testing there looked promising. This is a clinical trial, meaning the vaccine is being tested on humans after being successful on an animal. The government took this decision after the positive results of the first phase tests.

Each vaccinated person will be given two doses every four weeks as scheduled. The first dose is currently being given and the next dose will be given on the 29th. The vaccine is developed by Oxford University and the pharma company Astrazenka. It is named Covidshield. In India, the Pune-based Serum Institute of India has been approved to experiment with the vaccine.

Patients of different ages and with different backgrounds have been selected for the test at different levels in the country. All selected patients ranged in age from 18 to 55 years. The vaccine was also tested on 1,077 patients in Britain and was successful.

Serum: The world's largest vaccine manufacturer

The Serum Institute of Pune is the largest vaccine manufacturer in the world. Adar Poonawala is its CEO. Vaccines are being developed in many parts of the world, but Cerem decided to tie the knot with Oxford in April. Poonawala also clarified that if the vaccine is approved and his company produces it, half the vaccine will be given to India, half the dose will be sent to the world where it is decided. Serum has been mastering vaccine production for years and half of the various vaccines in the world are made in serum. Under normal circumstances serum can prepare 1.5 billion doses a year.

3 phases of clinical trials

When a drug or vaccine is ready, it is first used on organisms such as chimpanzees or mice. If it succeeds, then it should be experimented on human beings. The experiment on humans is called a clinical economic trial. This is a very important and dangerous phase of testing. Because the job of the vaccine is to heal the patient, but if something goes wrong, the vaccine that went into the body can have the opposite effect. So every step has to be filled with blows.

There are usually 3 stages to a human trial

In the first stage, patients are vaccinated in a very small group (20 to 80). If successful, more patients (100 to 300) will be dosed in the second phase. If all the results are positive then the third phase starts, in which a large number (1000 to 3000) people are given the dose. If successful, the vaccine is approved for widespread use and mass production is initiated.

Slow down the corona where BCG has been vaccinated

Researchers have also suggested that coronavirus appears to be slowing down in children where the BCG (Bacillia clementi Gurin) vaccine has been given to children. According to a report published in the American Association for the Advancement of Science, the BCG vaccine is acting as a wall to stop the spread of corona. BCG vaccine is given from childhood in many countries of India, China, Africa. However, there are more cases in India, as India's population is larger. But in terms of percentage, cases in India have been limited. The vaccine, originally recommended by the World Health Organization since 1949, aims to prevent TB. But it also plays an important role in preventing the spread of other diseases.